Atossa plans shareholder stake in potential PRV proceeds - Pharmaceutical Technology

Shareholders could be set for a cash reward if the biotech wins a voucher upon approval of (Z)-endoxifen. Shareholders could be set for a cash reward if the biotech wins a voucher upon approval of (Z)-endoxifen. Atossa’s CEO, Steven Quay, said the company believes its “shareholders should have a direct opportunity to participate if our rare disease programmes create the added value of a priority review voucher”. Credit: Cagkan Sayin/Shutterstock.com. Atossa Therapeutics has put in place a plan that would give its shareholders a share of any proceeds from the use or sale of a priority review voucher (PRV). PRVs…

Source: Pharmaceutical Technology